Dr. Theodore Berger’s research is currently focused primarily on the hippocampus, a neural system essential for learning and memory functions. Preclinical applications of Dr. Berger’s research include the development of cognitive neural prostheses for restoring lost memory; clinical applications extend to medical devices and procedures for controlling seizures; industrial applications include biologically-based models underlying spatio-temporal pattern recognition. His work was chosen as one of the “10 Breakthrough Technologies” of 2013 by the MIT Technology Review. Translation of some of Dr. Berger’s research has led to commercialization efforts through three start-up companies: Safety Dynamics, Inc., Rhenovia Pharma, Inc., and Neuralgenix, LLC. Dr. Theodore Berger received his Ph.D. from Harvard University in 1976; his thesis work received the James McKeen Cattell Award from the New York Academy of Sciences.